Vroege voorspelling adalimumab spiegels met InsightRx
Completed
- Conditions
- Inflammatory Bowel Diseases (M.Crohn and Ulcerative Colitis) and Rheumatic diseases (Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthropathy)
- Registration Number
- NL-OMON24282
- Lead Sponsor
- Máxima Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
All adult patients over 18 years of age with new adalimumab prescriptions at initial dosing interval of 14 days for rheumatic diseases (RA,PsA,SpA) or inflammatory bowel disease (UC, Crohn’s disease) will be eligible to participate in our study.
Exclusion Criteria
Pregnancy • Previous adalimumab use • Allergy for adalimumab or excipients (Humira) • Patients unable or unwilling to consent to participation to this trial
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method